Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/0974-9233.173133 http://scihub22266oqcxt.onion/10.4103/0974-9233.173133 C4759900!4759900 !26957836     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26957836 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26957836 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Middle+East+Afr+J+Ophthalmol 2016 ; 23 (1 ): 27-37 Nephropedia Template TP {{tp|p=26957836 |t=2016. Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials |pdf=|usr=}}{{26957836 }} gab.com Text Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials JO: Middle East Afr J Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=26957836 #FOAvip In the last decade, a number of prospective clinical trials with carefully designed study protocols have been conducted for the treatment of neovascular age-related macular degeneration (AMD). These landmark clinical trials such as ANCHOR and MARINA and, more recently, the Comparison of AMD Treatment Trials and VIEW studies have revolutionized the management of neovascular AMD. While AMD continues to remain a leading cause of severe visual loss worldwide, advances in pharmacotherapeutics have led to substantial improvements in the outcome of these patients. The introduction of anti-vascular endothelial growth factor agents has resulted in improvement of visual outcomes and has had a positive impact on the quality of life among elderly population. While the contemporary management of neovascular AMD has been successful in tremendously reducing the visual morbidity, the financial burden of therapy has increased exponentially. To overcome these challenges, newer pharmacologic agents are evaluated for their efficacy and safety in AMD. Ground-breaking advances in bench to bedside research have led to discovery of new pathways that appear to be viable targets for preventing visual loss in AMD. In this review, study designs and results of landmark clinical trials in AMD from the past decade have been summarized. Twit Text FOAVip Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials ????Middle East Afr J Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=26957836 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26957836 #FOAvip English Wikipedia <ref>{{Cite pmid|26957836 }}</ref> Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials #MMPMID26957836 Agarwal A ; Aggarwal K ; Gupta V Middle East Afr J Ophthalmol 2016[Jan]; 23 (1 ): 27-37 PMID26957836 show ga In the last decade, a number of prospective clinical trials with carefully designed study protocols have been conducted for the treatment of neovascular age-related macular degeneration (AMD). These landmark clinical trials such as ANCHOR and MARINA and, more recently, the Comparison of AMD Treatment Trials and VIEW studies have revolutionized the management of neovascular AMD. While AMD continues to remain a leading cause of severe visual loss worldwide, advances in pharmacotherapeutics have led to substantial improvements in the outcome of these patients. The introduction of anti-vascular endothelial growth factor agents has resulted in improvement of visual outcomes and has had a positive impact on the quality of life among elderly population. While the contemporary management of neovascular AMD has been successful in tremendously reducing the visual morbidity, the financial burden of therapy has increased exponentially. To overcome these challenges, newer pharmacologic agents are evaluated for their efficacy and safety in AMD. Ground-breaking advances in bench to bedside research have led to discovery of new pathways that appear to be viable targets for preventing visual loss in AMD. In this review, study designs and results of landmark clinical trials in AMD from the past decade have been summarized. |*Randomized Controlled Trials as Topic [MESH] |Angiogenesis Inhibitors/*therapeutic use [MESH] |Bevacizumab/therapeutic use [MESH] |Humans [MESH] |Intravitreal Injections [MESH] |Quality of Life/psychology [MESH] |Ranibizumab/therapeutic use [MESH] |Receptors, Vascular Endothelial Growth Factor/therapeutic use [MESH] |Recombinant Fusion Proteins/therapeutic use [MESH] |Vascular Endothelial Growth Factor A/antagonists & inhibitors [MESH] |Visual Acuity/drug effects/physiology [MESH]Management of Neovascular Age-related Macular Degeneration: A Review o(epmc).pdf DeepDyve Pubget Overpricing